Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Vaccine Sector Shows Signs Of Recovery Following Scandals, Popular Boycott

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In a sign that China's vaccine sector is beginning to recover from a series of scandals set in motion by allegations surrounding faulty products, the country's leading vaccine developer, Sinovac Biotech, has received a substantial new order for a hepatitis A defense that the Beijing government will administer to children across the capital

You may also be interested in...



CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red

BEIJING - The chief executive officer of Sinovac Biotech, China's leading vaccine developer, told investors this week that the country's latest vaccine scandal had poisoned public perceptions so deeply that many citizens are boycotting the entire sector

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC075292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel